At Surgical Sciences' Annual General Meeting on May 6, 2020, it was resolved to establish an incentive program of a maximum of 300,000 warrants for the company's employees. Each warrant gave the right to subscribe for one share in the company for SEK 85.10 during the period May 15 – July 15, 2023. A total of 225,000 options were subscribed for of the options program.

The options have now been exercised by the option holders which means that Surgical Science's share capital increases by SEK 11,250 and the number of shares increases by 225,000, corresponding to a dilution of approximately 0.4 percent of the total number of shares and votes. Surgical Science has thus received SEK 19,147,500 in cash.

In connection with the redemption procedure, CEO Gisli Hennermark has exercised 37,500 options, after which he has sold 37,500 shares. Gisli Hennermark's total shareholding in Surgical Science amounts to 342,200 shares after the transactions. CFO Anna Ahlberg has exercised 7,500 options, after which she has sold 6,000 shares. Anna Ahlberg's total shareholding in Surgical Science amounts to 24,000 shares after the transactions. The transactions are reported to the Swedish Financial Supervisory Authority in accordance with applicable regulations.

Following the exercise of the options, 181,900 shares have been sold to a few institutional investors in a process managed by Pareto Securities.

Gothenburg, Sweden, June 2, 2023
Surgical Science Sweden AB (publ)

The press release is available in the attachment or via

https://surgicalscience.com/aktien/pressmeddelanden/

This is a translation of the Swedish version of the press release. When in doubt, the Swedish wording prevails.